Biomet wins FDA clearance on two new products
The FDA has cleared Biomet to sell its E1 humeral bearing and Comprehensive Segmental Revision systems.
Biomet stated it designed the E1 for use with hip and knee devices. The company adapted the technology, which uses vitamin E to provide oxidative stability, for its Comprehensive Reverse Shoulder product line.
Comprehensive Segmental Revision is a system for replacing the humerus, typically in patients with bone cancer. The company designed it to be compatible with its shoulder and elbow systems.
Warsaw, Ind.-based Biomet’s primary market is musculoskeletal surgery.
Biomet stated it designed the E1 for use with hip and knee devices. The company adapted the technology, which uses vitamin E to provide oxidative stability, for its Comprehensive Reverse Shoulder product line.
Comprehensive Segmental Revision is a system for replacing the humerus, typically in patients with bone cancer. The company designed it to be compatible with its shoulder and elbow systems.
Warsaw, Ind.-based Biomet’s primary market is musculoskeletal surgery.
Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.